Raltegravir with optimized background therapy for resistant HIV-1 infection
about
Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of actionVirological and cellular roles of the transcriptional coactivator LEDGF/p75A report of lung adenocarcinoma with HIV carrier and the literature reviewP2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran MoietyA new class of multimerization selective inhibitors of HIV-1 integraseLong-term efficacy and safety of raltegravir in the management of HIV infection.Approved Antiviral Drugs over the Past 50 YearsDolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trialsDrug-class specific impact of antivirals on the reproductive capacity of HIVThe effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trialRaltegravir cerebrospinal fluid concentrations in HIV-1 infectionTransmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97AClinical use of HIV integrase inhibitors: a systematic review and meta-analysisNon-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cellsSwitching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNAResponse of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.Assessing overall evidence from noninferiority trials with shared historical data.Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral TherapyA note on partial covariate-adjustment and design considerations in noninferiority trials when patient-level data are not available.HIV integrase inhibitors: a new era in the treatment of HIV.Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North AmericaDolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studyImpact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversionVirological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine CohortSimilar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or CEfficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapyRaltegravir: The evidence of its therapeutic value in HIV-1 infection.Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.
P2860
Q24316120-6547CA44-B1D8-42E0-B236-7744C458FA2EQ24634176-8D97661C-42DB-4E9B-A557-B9F3E603A2ECQ26820860-5A50F761-277F-4115-8300-132853078906Q27679177-ABF36A56-A49A-448F-B502-B8A7DD736C4EQ27683994-F403BDDC-A8AF-447B-AB1D-7321C7A046BCQ27686870-41A756E8-A672-4FCA-93A9-AE97252C75A9Q27755387-23E3F5B5-6933-45AC-921F-959B8033B805Q28077053-FD76EC7A-87E2-4A28-8F23-003820376DA4Q28473451-3B40A4CE-AF5E-4A53-9A9A-0C41A10D2BECQ28475076-B92FF649-89C7-406C-BB68-873923A78007Q28476050-1E7B2A46-DAC0-4A10-B2DD-6A086E651269Q28476489-739D72EE-FB96-4439-BD58-EE961FF9291FQ28478722-CB735F8F-4C67-4EDB-B9D9-C763DE1832CEQ28484930-EAACE042-805D-40E9-AFF6-9AA43807B715Q28536951-7130EF6A-37BC-4C80-960C-025B610AF439Q28731610-DE76B862-BF5F-4C0B-A34C-5AF576E35EA7Q30494064-D42C7824-2CE5-495B-BC26-57FD155416B0Q30567163-52743C64-208C-454D-8804-110F7D45F3D7Q30609066-2FECB09E-E9BA-482A-B0BB-33D0FAF87FE1Q30662286-429E61C0-AE8F-4E96-A364-EAD6E79A20A7Q30956943-D346E696-E094-4BEA-857D-C7014B98B20CQ33559015-D68D4762-3228-4915-84E2-47208D669CDBQ33559216-77C1D411-7648-4B52-BE4B-9BFBF2B34A18Q33570427-E3B444EE-2358-4530-A7D3-3C31B1E0D92DQ33613775-EDC37ED7-955E-432A-9CA2-D6A51DD9D88AQ33629439-E64FF891-05B7-4AA2-8FDF-8A020F4BE601Q33853922-55DD9B96-3576-4026-8FEA-6686315C9180Q33880221-D470E7EA-57AA-42BD-8D21-6E9C0EADCB2DQ33887352-F997CB05-7270-4ACF-9050-CB28129260A0Q33888718-08549029-49B4-49F1-879A-0C01C67E7236Q33888845-BFECB4AF-DD95-42D8-B90A-D2AC58763B91Q33910771-B8F16F02-973C-46D1-9E88-AC2005021AA9Q33910849-D2D5CC7A-88D3-4A3A-8607-17614130AABAQ33931265-841247B7-5233-431B-8C48-F2E02920F951Q33935930-1338CA63-67D7-4EFB-B0E7-99B77E62E722Q33940800-6B6875CE-6B86-48F8-B488-0B072A3E0B42Q33945171-55D92903-F69D-4CC7-B7D9-CB3D3131A753Q33962223-44CE2517-A896-481E-84A3-89E6F609DCD8Q33973930-076DF7FA-D1A8-4785-95FA-A4AC2BD72640Q34035275-CCBDDFFE-E77A-4D74-95F6-D913F701DE89
P2860
Raltegravir with optimized background therapy for resistant HIV-1 infection
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Raltegravir with optimized background therapy for resistant HIV-1 infection
@ast
Raltegravir with optimized background therapy for resistant HIV-1 infection
@en
Raltegravir with optimized background therapy for resistant HIV-1 infection
@nl
type
label
Raltegravir with optimized background therapy for resistant HIV-1 infection
@ast
Raltegravir with optimized background therapy for resistant HIV-1 infection
@en
Raltegravir with optimized background therapy for resistant HIV-1 infection
@nl
prefLabel
Raltegravir with optimized background therapy for resistant HIV-1 infection
@ast
Raltegravir with optimized background therapy for resistant HIV-1 infection
@en
Raltegravir with optimized background therapy for resistant HIV-1 infection
@nl
P2093
P50
P3181
P356
P1476
Raltegravir with optimized background therapy for resistant HIV-1 infection
@en
P2093
Anne R Meibohm
Bach-Yen Nguyen
Daria J Hazuda
David A Cooper
Desmond M Ryan
Hedy Teppler
Jeffrey L Lennox
John A Killar
Jose M Gatell
P304
P3181
P356
10.1056/NEJMOA0708975
P407
P577
2008-07-24T00:00:00Z